Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials

Caryn Lerman, Christopher Jepson, E. Paul Wileyto, Leonard H. Epstein, Margaret Rukstalis, Freda Patterson, Vyga Kaufmann, Stephanie Restine, Larry Hawk, Raymond Niaura, Wade Berrettini

Research output: Contribution to journalArticle

Abstract

Although bupropion and nicotine replacement therapy (NRT) are efficacious tobacco dependence treatments, there is substantial interindividual variability in therapeutic response and most smokers relapse. Pharmacogenetics research may improve treatment outcomes by identifying genetic variants predictive of therapeutic response. We investigated the roles of two functional genetic variants in the dopamine D2 receptor (DRD2) gene in response to pharmacotherapy for tobacco dependence among participants in two randomized clinical trials with a 6-month follow-up period: a double-blind placebo-controlled trial of bupropion (n = 414) and an open label trial of transdermal nicotine vs nicotine nasal spray (n = 368). At the end of the treatment phase, a statistically significant (p = 0.01) interaction between the DRD2 -141C Ins/Del genotype and treatment indicated a more favorable response to bupropion among smokers homozygous for the Ins C allele compared to those carrying a Del C allele. By contrast, smokers carrying the Del C allele had statistically significantly (p = 0.006) higher quit rates on NRT compared to those homozygous for the Ins C allele, independent of NRT type. The C957T variant was also associated (p = 0.03) with abstinence following NRT. These results suggest that bupropion may be the preferred pharmacologic treatment for smokers homozygous for the DRD2 -141 Ins C allele, while NRT may be more beneficial for those who carry the Del C allele. Study findings require confirmation in additional larger samples before they are applied in practice.

Original languageEnglish (US)
Pages (from-to)231-242
Number of pages12
JournalNeuropsychopharmacology
Volume31
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Bupropion
Tobacco Use Disorder
Dopamine D2 Receptors
Nicotine
Randomized Controlled Trials
Alleles
Therapeutics
Tobacco Use Cessation Products
Pharmacogenetics
Genotype
Placebos

Keywords

  • Bupropion
  • Dopamine
  • Genetics
  • Nicotine
  • Smoking
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence : Results of two randomized clinical trials. / Lerman, Caryn; Jepson, Christopher; Wileyto, E. Paul; Epstein, Leonard H.; Rukstalis, Margaret; Patterson, Freda; Kaufmann, Vyga; Restine, Stephanie; Hawk, Larry; Niaura, Raymond; Berrettini, Wade.

In: Neuropsychopharmacology, Vol. 31, No. 1, 01.2006, p. 231-242.

Research output: Contribution to journalArticle

Lerman, Caryn ; Jepson, Christopher ; Wileyto, E. Paul ; Epstein, Leonard H. ; Rukstalis, Margaret ; Patterson, Freda ; Kaufmann, Vyga ; Restine, Stephanie ; Hawk, Larry ; Niaura, Raymond ; Berrettini, Wade. / Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence : Results of two randomized clinical trials. In: Neuropsychopharmacology. 2006 ; Vol. 31, No. 1. pp. 231-242.
@article{bf69d77e2f38478b813b364c48fe33cb,
title = "Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials",
abstract = "Although bupropion and nicotine replacement therapy (NRT) are efficacious tobacco dependence treatments, there is substantial interindividual variability in therapeutic response and most smokers relapse. Pharmacogenetics research may improve treatment outcomes by identifying genetic variants predictive of therapeutic response. We investigated the roles of two functional genetic variants in the dopamine D2 receptor (DRD2) gene in response to pharmacotherapy for tobacco dependence among participants in two randomized clinical trials with a 6-month follow-up period: a double-blind placebo-controlled trial of bupropion (n = 414) and an open label trial of transdermal nicotine vs nicotine nasal spray (n = 368). At the end of the treatment phase, a statistically significant (p = 0.01) interaction between the DRD2 -141C Ins/Del genotype and treatment indicated a more favorable response to bupropion among smokers homozygous for the Ins C allele compared to those carrying a Del C allele. By contrast, smokers carrying the Del C allele had statistically significantly (p = 0.006) higher quit rates on NRT compared to those homozygous for the Ins C allele, independent of NRT type. The C957T variant was also associated (p = 0.03) with abstinence following NRT. These results suggest that bupropion may be the preferred pharmacologic treatment for smokers homozygous for the DRD2 -141 Ins C allele, while NRT may be more beneficial for those who carry the Del C allele. Study findings require confirmation in additional larger samples before they are applied in practice.",
keywords = "Bupropion, Dopamine, Genetics, Nicotine, Smoking, Treatment",
author = "Caryn Lerman and Christopher Jepson and Wileyto, {E. Paul} and Epstein, {Leonard H.} and Margaret Rukstalis and Freda Patterson and Vyga Kaufmann and Stephanie Restine and Larry Hawk and Raymond Niaura and Wade Berrettini",
year = "2006",
month = "1",
doi = "10.1038/sj.npp.1300861",
language = "English (US)",
volume = "31",
pages = "231--242",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence

T2 - Results of two randomized clinical trials

AU - Lerman, Caryn

AU - Jepson, Christopher

AU - Wileyto, E. Paul

AU - Epstein, Leonard H.

AU - Rukstalis, Margaret

AU - Patterson, Freda

AU - Kaufmann, Vyga

AU - Restine, Stephanie

AU - Hawk, Larry

AU - Niaura, Raymond

AU - Berrettini, Wade

PY - 2006/1

Y1 - 2006/1

N2 - Although bupropion and nicotine replacement therapy (NRT) are efficacious tobacco dependence treatments, there is substantial interindividual variability in therapeutic response and most smokers relapse. Pharmacogenetics research may improve treatment outcomes by identifying genetic variants predictive of therapeutic response. We investigated the roles of two functional genetic variants in the dopamine D2 receptor (DRD2) gene in response to pharmacotherapy for tobacco dependence among participants in two randomized clinical trials with a 6-month follow-up period: a double-blind placebo-controlled trial of bupropion (n = 414) and an open label trial of transdermal nicotine vs nicotine nasal spray (n = 368). At the end of the treatment phase, a statistically significant (p = 0.01) interaction between the DRD2 -141C Ins/Del genotype and treatment indicated a more favorable response to bupropion among smokers homozygous for the Ins C allele compared to those carrying a Del C allele. By contrast, smokers carrying the Del C allele had statistically significantly (p = 0.006) higher quit rates on NRT compared to those homozygous for the Ins C allele, independent of NRT type. The C957T variant was also associated (p = 0.03) with abstinence following NRT. These results suggest that bupropion may be the preferred pharmacologic treatment for smokers homozygous for the DRD2 -141 Ins C allele, while NRT may be more beneficial for those who carry the Del C allele. Study findings require confirmation in additional larger samples before they are applied in practice.

AB - Although bupropion and nicotine replacement therapy (NRT) are efficacious tobacco dependence treatments, there is substantial interindividual variability in therapeutic response and most smokers relapse. Pharmacogenetics research may improve treatment outcomes by identifying genetic variants predictive of therapeutic response. We investigated the roles of two functional genetic variants in the dopamine D2 receptor (DRD2) gene in response to pharmacotherapy for tobacco dependence among participants in two randomized clinical trials with a 6-month follow-up period: a double-blind placebo-controlled trial of bupropion (n = 414) and an open label trial of transdermal nicotine vs nicotine nasal spray (n = 368). At the end of the treatment phase, a statistically significant (p = 0.01) interaction between the DRD2 -141C Ins/Del genotype and treatment indicated a more favorable response to bupropion among smokers homozygous for the Ins C allele compared to those carrying a Del C allele. By contrast, smokers carrying the Del C allele had statistically significantly (p = 0.006) higher quit rates on NRT compared to those homozygous for the Ins C allele, independent of NRT type. The C957T variant was also associated (p = 0.03) with abstinence following NRT. These results suggest that bupropion may be the preferred pharmacologic treatment for smokers homozygous for the DRD2 -141 Ins C allele, while NRT may be more beneficial for those who carry the Del C allele. Study findings require confirmation in additional larger samples before they are applied in practice.

KW - Bupropion

KW - Dopamine

KW - Genetics

KW - Nicotine

KW - Smoking

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=32844456518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844456518&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300861

DO - 10.1038/sj.npp.1300861

M3 - Article

VL - 31

SP - 231

EP - 242

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -